Retatrutide

Retatrutide is a synthetic tri-agonist peptide studied for its interaction with glucagon-like peptide-1 (GLP-1), it is currently under investigation for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). it is a glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors in experimental metabolic models. It is structurally engineered to enhance stability and multi-receptor engagement. Preclinical research utilizes Retatrutide to investigate receptor binding kinetics, coordinated cAMP-mediated intracellular signaling pathways, and integrated endocrine signaling mechanisms under controlled laboratory conditions. For research use only.